Latest Breaking News On - Jubilant therapeutics - Page 5 : comparemela.com

How Soon Should You Start Planning For Drug Commercialization

How Soon Should You Start Planning For Drug Commercialization
clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.

Syed kazmiEd misetaChief editorJubilant therapeuticsJubilant therapeuticskazmiசையத் காஜ்மிதலைமை ஆசிரியர்மகிழ்ச்சி சிகிச்சை

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restoration and immune-mediated tumor growth suppression - Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology BEDMINSTER, N.J., April 10, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing oral, small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data from two programs evaluating the company s PRMT5 inhibitor and PD-L1 inhibitor as anti-cancer agents, will be presented today in a poster session at the American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually from April 10-15, 2021.

United statesAmericanKostenloser wertpapierhandelSyed kazmiDhanalakshmi sivanandhanAmerican association for cancer researchLinkedinPrnewswire jubilant therapeutics incJubilant therapeutics incJubilant pharmovaTherapeutics incAmerican associationCancer researchChief executive officerJubilant therapeuticsDaylight time

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

Share this article Share this article BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer. Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community. Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team, said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics. His experience and leadership advancing novel targeted therapeutics will be integral as we execute our corporate vision.

GenevaGeneSwitzerlandUnited statesAmericanLuca rastelliSerono merckSyed kazmiDepartment of neuroPrnewswire jubilant therapeutics incKleo pharmaceuticalsUniversity of genevaAmerican brain tumor associationMd anderson cancer centerTherapeutics incChief scientific

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

(1) BEDMINSTER, N.J., Feb. 25, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with Boston Children s Hospital (https://wistar.org/) to evaluate peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics to explore the modulation of neutrophil extracellular traps (NETosis) in preclinical models of neutrophil regulation and rheumatoid arthritis (RA). PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS.

BostonMassachusettsUnited statesKostenloser wertpapierhandelSyed kazmiDenisa wagnerLinkedinHarvard medical schoolJubilant therapeutics incJubilant life sciencesNational academy of medicineNational academy of sciencesProgram in cellularYoutubePrnewswire jubilant therapeutics incFacebook

Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs

Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs News provided by Share this article Share this article NEW HAVEN, Conn. and BENGALURU, India, Feb. 9, 2021 /PRNewswire/ Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs. Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology among others. Yale Logo Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said Yale is one of the top-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to support scientific endeavours of Investigators at Yale to pursue novel target ideas for unmet medical conditions. With our New Discove

IndiaCanadaBengaluruKarnatakaMarcel velteropBlavatnik fund for innovation at yaleYale office of cooperative researchOffice of cooperative researchJubilant therapeutics incDevelopment servicesJubilant life sciencesJubilant pharmovaJubilant pharmaContract researchJubilant biosysPresident jubilant biosys